Dr. Sandhya Ramanathan Panch, MD

Dr. Panch practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Panch's NPI, 1003043415, was assigned on June 12, 2009. Dr. Panch holds Washington license MD61178990.

Dr. Panch's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Panch's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Dr. Panch is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Panch practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Panch's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Panch is board certified in hematology by the American Board of Internal Medicine. Dr. Panch is licensed in Washington.

CMS data shows 168 Medicare services from Dr. Panch across 3 procedure codes in 2024, for 132 Medicare patients. Medicare paid $9,204 for them.

CMS counts 132 Medicare patients who saw Dr. Panch in 2024. The largest group is 75 to 84, with 57 patients. 67% of them have high blood pressure, and 60% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Panch's median patient age at 57, with 57% women.

In 2024, Dr. Panch wrote 21 Medicare Part D claims. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $10,063 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Panch for performance year 2024, reported through an alternative payment model (APM). Dr. Panch accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Panch as offering telehealth.

Dmand AI links 58 papers to Dr. Panch, published from 2011 to 2025. 2022 was the busiest year, with 8. The most frequent topics are Receptors, Chimeric Antigen, Hematopoietic Stem Cell Transplantation and Immunotherapy, Adoptive. Dr. Panch has published most often in Transfusion. Dr. Panch's most frequent co-authors are Ping Jin, MD, Cynthia Elizabeth Dunbar, MD and Susan Flora Leitman, MD.

Dmand AI links Dr. Panch to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 114 general payments to Dr. Panch from 14 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 62% of the total. Sobi, Inc paid the most, $84,826. It also lists 2 research payments totaling $1,221 in 2025.